drugset / Trial / NCT04112316
Developing Oral LT3 Therapy for Heart Failure - HFrEF
Phase 1/2
Completed
28 enrolled
University of Pennsylvania
National Heart, Lung, and Blood Institute (NHLBI) · collab
RandomizedCrossoverTriple-blindTreatment
Summary
Investigation of the safety, feasibility, and preliminary efficacy of thyroid hormone therapy with Liothyronine (LT3) in individuals with heart failure with reduced ejection fraction (HFrEF) and low triiodothyronine (T3) syndrome by conducting a randomized, double-blind, placebo-controlled cross-over study with a two-week washout period between treatments.
Timeline
- Start
- 2020-02-11
- Primary completion
- 2023-10-31
- Completion
- 2023-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Liothyronine | Unknown | 2.5 ug | Oral |
| Comparator | Liothyronine | Unknown | 12.5 ug | Oral |